OncoPharm

We welcome Dr. Donald Harvey to the podcast to discuss Phase 1 clinical trials in oncology. Topics include goals of Phase 1 trials, how these early studies are conducted, how doses are determined, and some limitations of current practices.

We welcome Jacqueline (Jackie) Saunders to the podcast to talk about investigational drug services (IDS) in oncology and how pharmacists manage the storage, preparation, & delivery of experimental drugs.

This episode...

More evidence to support the use of neoadjuvant ICI/chemo in stage III NSCLC to obtain pCR published this week with NADIM II.

Time to rethink giving ICI/TKI combination therapy to favorable-risk metastatic RCC patients? (Finally, I'm not the only one saying this anymore.)

NADIM II: https://www.nejm.org/doi/full/10.1056/NEJMoa2215530

FDA Pooled Analysis Favorable Risk metastatic RCC: https://doi.org/10.1016/j.eururo.2023.05.030

This week's Pod looks at the 2nd CD20-CD3 bispecific T-Cell engager approved this year (or at all), glofitamab, and the TALAPRO-2 study of combining talazoparib to enzalutaimide.

TALAPRO-2: https://doi.org/10.1016/S0140-6736(23)01055-3

We highlight notable data from this month's ASCO annual meeting.

1. SONIA: sequence (1st or 2nd-line) CKD 4/6i in MBC

2. ADAURA OS results and low rate of osimertinib use in control arm

3. Keynote 671: perioperative pembrolizumab in NSCLC

4. PROSPECT: Can radiation therapy be omitted in locally advanced rectal cancer?

5. Nivo-AVD vs. Bv-AVD in stage III Hodgkin's (ages 12+)

6. ZUMA-7: 2nd line Axl-Cel OS benefit in aggressive NHL (early relapse/refractory disease)

7. CARTITUDE-4: Cilta-Cel earlier in MM treatment

ASCO '23 Appetizers by John Bossaer

Olaparib + Abiraterone is FDA approved for mutated-BRCA prostate cancers. Olaparib has a bit of convoluted story to unpack in this patient population.

Have we finally found a way to minimize the peripheral neuropathy from paclitaxel.....with cilostazol?

PROpel: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043

Cilostazol RCT: https://doi.org/10.1002/phar.2830

Cilostazol effect on Schwann cells: https://doi.org/10.1016/j.neuropharm.2021.108514

We discuss the newly approved CD20-CD3 T-cell engager for subcutaneous (SC) administration to treat DLBLC after 2 or more lines of therapy.

A recent paper serves as a good prompt to discuss trimodality treatment for muscle-invasive bladder cancer and the data supporting its use.

Zlotta et al: https://doi.org/10.1016/S1470-2045(23)00170-5

Today's Pod discusses...

1) A large trial comparing 4 different CLL treatments

GAIA-CLL13: https://www.nejm.org/doi/full/10.1056/NEJMoa2213093

2)Adding Cabozantinib + Nivo/Ipo vs. Nivo/Ipi in intermediate/poor risk mRCC

COSMIC-313: https://www.nejm.org/doi/full/10.1056/NEJMoa2212851

3) A potential future biomarker for predicting response to PD-(L)1 targeted therapies

Functional PD-1/PD-L1 Engagement: https://pubmed.ncbi.nlm.nih.gov/?term=36821809